* Apyx Medical Corp APYX.OQ APYX.O is expected to show a
rise
in quarterly revenue when it reports results on May 12.
* The Clearwater Florida-based company is expected to
report a
28.8% increase in revenue to $11.122 million from $8.64 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Apyx Medical Corp
is for
a loss of 15 cents per share. For the same quarter last year,
the company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Apyx
Medical Corp
is $15, above its last closing price of $3.22.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.10 -0.11 -0.06 Beat 45.5
Sep. 30 2021 -0.15 -0.15 -0.12 Beat 20
Jun. 30 2021 -0.16 -0.15 -0.12 Beat 18.5
Mar. 31 2021 -0.14 -0.14 -0.14 Met 1.8
Dec. -0.11 -0.11 -0.04 Beat 64.3
31 2020
Sep. 30 2020 -0.16 -0.17 -0.11 Beat 33.4
Jun. 30 2020 -0.20 -0.21 -0.14 Beat 34.1
Mar. 31 2020 -0.25 -0.25 -0.20 Beat 20
This summary was machine generated May 10 at 18:30 GMT. All
figures in US dollars unless otherwise stated